Medullary Thyroid Cancer - Pipeline Insight, 2026

DelveInsight's, "Medullary Thyroid Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Medullary Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Medullary Thyroid Cancer: Understanding

Medullary Thyroid Cancer: Overview

Medullary thyroid cancer (MTC) is a relatively uncommon type of thyroid malignancy that originates from the parafollicular C cells of the thyroid gland, which are responsible for producing calcitonin. It accounts for a small proportion of all thyroid cancers, typically around 1-5%, but is clinically significant due to its distinct biological behavior compared to more common thyroid cancers. MTC often demonstrates a more aggressive course and a greater tendency for early spread to lymph nodes and distant sites. Its unique cellular origin and secretion of calcitonin also make it biologically and clinically distinct within the spectrum of thyroid malignancies.

Medullary thyroid cancer arises from thyroid parafollicular C cells and is mainly driven by activating mutations in the RET proto-oncogene. These mutations trigger key signaling pathways like MAPK and PI3K-AKT, leading to uncontrolled cell growth and progression from C-cell hyperplasia to cancer. It occurs in both sporadic and hereditary forms (MEN2-associated) and retains neuroendocrine features, including calcitonin secretion. Over time, the tumor can become locally invasive and may metastasize to regional lymph nodes and distant organs.

The primary cause of this cancer is genetic alterations in the RET proto-oncogene, which regulates growth and differentiation of thyroid C cells. Hereditary cases are mainly linked to germline RET mutations associated with MEN2 syndromes, while sporadic cases often involve somatic RET or RAS mutations. These changes lead to continuous activation of growth signaling pathways, resulting in uncontrolled C-cell proliferation and malignant transformation.

Medullary thyroid cancer (MTC) is diagnosed through a combination of clinical evaluation, biochemical testing, imaging, and confirmatory pathology. Elevated serum calcitonin levels are a key diagnostic marker, often reflecting tumor burden, while carcinoembryonic antigen (CEA) may also be increased. Fine-needle aspiration cytology of thyroid nodules helps in confirming malignancy, and genetic testing for RET mutations is routinely used, especially to identify hereditary cases associated with MEN2 syndromes.

The primary treatment for medullary thyroid cancer is surgical removal of the thyroid, often with lymph node dissection due to early spread. It is generally resistant to radioactive iodine and TSH suppression therapy, so management relies on surgery and monitoring of calcitonin and CEA levels. In advanced cases, tyrosine kinase inhibitors may be used to slow disease progression.

"Medullary Thyroid Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medullary Thyroid Cancer pipeline landscape is provided which includes the disease overview and Medullary Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Medullary Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medullary Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Medullary Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Medullary Thyroid Cancer.

Medullary Thyroid Cancer Emerging Drugs Chapters

This segment of the Medullary Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Medullary Thyroid Cancer Emerging Drugs

• Regorafenib: Bayer Healthcare

Regorafenib is an oral targeted kinase inhibitor which works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that tumors need to grow. Blocking these signals keeps cancer cells from growing and spreading to other parts of the body. It is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug. It targets multiple signaling pathways involved in tumor growth and angiogenesis, including VEGFR, RET, RAF, and KIT kinases, thereby inhibiting both cancer cell proliferation and tumor vascularization. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of medullary thyroid cancer.

• APS03118: Applied Pharmaceutical Science

APS03118 is a second generation selective RET inhibitor which shows remarkable potency against various RET fusion and mutations at the nanomolar level including gatekeeper V804 and solvent frontier G810 mutation that induces the resistance of the first generation of selective RET inhibitors. Dose-dependent antitumor activity and well tolerability of APS03118 were observed in mice models, especially in mice intracranial tumor model with complete regression of brain tumor and 100% mice survival. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of medullary thyroid cancer.

Medullary Thyroid Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Medullary Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Medullary Thyroid Cancer

There are approx. 8+ key companies which are developing the therapies Medullary Thyroid Cancer. The companies which have their Medullary Thyroid Cancer drug candidates in the most advanced stage, i.e. Phase III include, Bayer Healthcare, and others.

• Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Medullary Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Medullary Thyroid Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medullary Thyroid Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medullary Thyroid Cancer drugs.

Medullary Thyroid Cancer Report Insights

• Medullary Thyroid Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Medullary Thyroid Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Medullary Thyroid Cancer drugs?
• How many Medullary Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medullary Thyroid Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medullary Thyroid Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Medullary Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bayer Healthcare
• Applied Pharmaceutical Science

Key Products

• Regorafenib
• APS0311